Skip to main content
Name the biomarker and attach a folder of publications on its clinical performance. Anara synthesizes the published sensitivity and specificity range, the patient populations studied, how it compares to the gold standard, and which guidelines have endorsed its use. Every data point cites the specific paper it came from. For clinical development and medical affairs teams building the evidence foundation for a biomarker’s regulatory or market access case.

​
1. Describe the task

Your biomarker has a growing literature. Papers across different patient populations, study designs, and device platforms, each reporting performance data that is hard to synthesize in your head and time-consuming to pull together manually. Anara reads across the papers you have collected and organizes the clinical performance evidence into a structured synthesis: the published sensitivity and specificity range across studies, which patient populations have been studied and which have not, how the biomarker performs against the gold standard, what the outstanding clinical questions are, and which regulatory or clinical guidelines have formally endorsed its use. Every data point in the synthesis cites the specific paper and the specific passage it came from. The synthesis is useful at two stages. Early in a development program, it maps what the literature has established and where the clinical gaps are, which shapes the study design for the next validation study. Later, it becomes the evidence foundation for a regulatory submission or a market access dossier, where every clinical claim must trace to a published source. Here a clinical research scientist at a medical diagnostics company is building the evidence case for a novel cardiac biomarker as an alternative to endomyocardial biopsy in transplant monitoring, and has a folder of twenty-three publications. 
I am building a clinical evidence case for donor-derived cell-free DNA (dd-cfDNA) as a non-invasive alternative to endomyocardial biopsy for detecting cardiac allograft vasculopathy and rejection. My publications are in the folder "dd-cfDNA Cardiac Evidence."

Across these papers, synthesize:
1. The published sensitivity and specificity range for dd-cfDNA across the included studies (report the range with the studies at each end of the range)
2. Which patient populations have been studied (transplant type, timing post-transplant, center characteristics)
3. How dd-cfDNA performance compares to endomyocardial biopsy as the reference standard, including any studies reporting concordance data
4. Which clinical guidelines or professional societies have formally endorsed or reviewed dd-cfDNA in this indication
5. The outstanding clinical questions not yet answered by the published literature

Use only papers in my folder. Cite the specific paper and passage for every data point. Flag any performance claim where fewer than three papers agree.

​
2. Give Anara context

Required context
  • A folder containing the publications you want synthesized.
Optional context
  • The specific regulatory or market access context you are building toward (EU MDR clinical evaluation, FDA 510(k), HEOR submission). Anara adjusts the framing and depth of evidence classification.
  • One or two papers you consider anchor studies. Anara treats these as primary references and ensures every other paper is compared against their methodology and findings.

​
3. What Anara creates

A structured clinical evidence synthesis covering the performance dimensions you named, with per-claim citations and a summary of the outstanding gaps. The synthesis is the working evidence document you bring to a clinical development team meeting, a regulatory submission, or a market access dossier. Where fewer than three papers agree on a performance claim, the output flags that so you know where your evidence base is thin before a reviewer identifies it for you.

​
4. Follow-up prompts

​
Identify the outstanding clinical questions

When the synthesis is complete and you want to map the gaps for the next study design. 
Based on the evidence synthesis, identify the three most significant gaps in the published literature that limit the clinical adoption case for dd-cfDNA. For each gap, describe what study design would most credibly address it.

​
Compare this biomarker’s evidence base to an established comparator

When you need to position the biomarker against the current standard of care or a competing technology. 
Compare the published performance data for dd-cfDNA against the endomyocardial biopsy data in my folder. Where does dd-cfDNA show superior, inferior, or equivalent performance? Cite the studies that provide the most direct head-to-head comparison.

​
Write the clinical evidence summary paragraph

When the synthesis is complete and you need a concise narrative for a submission or a regulatory filing. 
Write a 200-word clinical evidence summary for dd-cfDNA based on the synthesis. Use formal regulatory language suitable for a clinical evaluation report. Every claim must trace to the cited papers in the folder. Flag any claim where the evidence comes from fewer than two independent studies.

​
5. Tricks, tips, and troubleshooting

​
How you word your prompt shapes what you get

Naming the specific performance dimensions you need (sensitivity, specificity, concordance, guideline endorsement) produces a structured synthesis organized around those dimensions. Without named dimensions, Anara produces a general summary that may not align with the structure your regulatory or market access submission requires. The instruction to flag claims supported by fewer than three papers is important: single-study performance claims are a standard target for regulatory scrutiny, and knowing in advance where your evidence base is thin lets you decide whether to qualify those claims or commission new evidence before submission.

​
Check the output against your own understanding

Performance data across studies is not always directly comparable: different patient populations, different reference standards, different analytical platforms can all shift the reported numbers. Before presenting the synthesized range to a regulatory body, review the papers at the extremes of the range and confirm the methodology is comparable to the studies in the middle. If the range spans studies with fundamentally different designs, the synthesis needs a note explaining that, not just a number.

​
What to do with the output next

Use the synthesis as the clinical evidence section of a regulatory filing or a market access dossier. For regulatory submissions, pair it with the appraisal table workflow to ensure every study has a formal quality assessment row. For market access, use the outstanding questions section to frame unmet evidence needs in the health economic model.